axinn

IPR v. Ex Parte Reexam Strategy Considerations

1 MIN READ


February 7, 2024, 7:16 AM

Looking forward to presenting at the AIPLA IP Practice in Japan Mid-Winter Program in Houston, TX next week!

I will be discussing the strategic considerations for *Inter Partes* Review (IPR) versus *Ex Parte* Reexamination, including:

- The procedural differences between IPR and *Ex Parte* Reexamination and associated statistics
- The circumstances when one may be preferable over the other
- The effects of timing and estoppel in parallel litigations

My colleague, <u>Jason Murata</u>, another partner in Axinn's Intellectual Property group, will be covering, "Recent Developments in the Generic Pharma Industry in the U.S."



Related Services

Intellectual Property

To subscribe to our publications, click here.

News & Insights

- GCR Live: Law Leaders Europe 2025
 SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
 SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting

Businesses webinar antitrust

- NJSBA Annual Meeting and Convention 2025
 SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies Making Paragraph IV Litigation Work for You

WEBINAR INTELLECTUAL PROPERTY

- Hartford HealthCare Black and Red Gala 2025
 sponsorship ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
 sponsorship ANTITRUST
- Five Healthcare Antitrust Topics to Watch at the Upcoming Health Care Transactions Conference in Nashville
 AXINN VIEWPOINTS ANTITRUST

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved